Group 1 - The core viewpoint of the article highlights the recognition of Linuo Pharmaceutical Packaging (力诺药包) as a leading company in the A-share market, winning two awards for "A-share Growth Demonstration Case" and "Outstanding Secretary" at the 2025 China Listed Company Excellence Case Selection [1] - The 2025 China Listed Company Excellence Case Selection aims to promote high-quality development in China's capital market, advocating for value and long-term investment principles, with evaluations based on operational performance and governance levels [1] - Linuo Pharmaceutical Packaging, established in 1995, is a high-tech enterprise specializing in glass new materials, with a complete industry chain and advanced technology, gaining global customer recognition [1] Group 2 - In the pharmaceutical packaging sector, Linuo focuses on the research and application of pharmaceutical glass packaging materials, overcoming technical bottlenecks in borosilicate glass melting and forming, and establishing a complete industrial chain from tube to bottle [2] - The company has a production capacity of 150 million pieces of heat-resistant glass products annually and is recognized as Asia's leading borosilicate glass production base [2] - Linuo has initiated a major high-end pharmaceutical packaging project in 2023, with a total investment of 2 billion yuan, integrating automation, information technology, 5G, AI, big data, and digital twin technology [2] Group 3 - Linuo Pharmaceutical Packaging adheres to an innovation-driven development strategy, balancing environmental protection, social responsibility, and governance capabilities, aiming to become a trusted global pharmaceutical packaging enterprise [3] - The recent awards reflect the capital market's deep recognition of Linuo's long-term value and resilience in development [3] - The company aims to inject vitality into the high-quality development of the pharmaceutical packaging industry while following its corporate vision of becoming a trusted partner for global customers [3]

Core Viewpoint - The company Lino Pharmaceutical announced that the "Lino Convertible Bond" will resume conversion into shares starting from September 19, 2025, following the end of the repurchase application period [2] Group 1 - The announcement was made on the evening of September 18 [2] - The resumption of conversion is significant for investors holding the convertible bonds [2]

| 证券代码：301188 | 证券简称：力诺药包 | 公告编号：2025-088 | | --- | --- | --- | | 债券代码：123221 | 债券简称：力诺转债 | | 山东力诺医药包装股份有限公司 关于"力诺转债"恢复转股的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、债券代码：123221 债券简称：力诺转债 2、转股期限：2024 年 2 月 29 日至 2029 年 8 月 22 日止 4、恢复转股时间：2025 年 9 月 19 日 根据中国证券监督管理委员会《关于同意山东力诺特种玻璃股份有限公司向 不特定对象发行可转换公司债券注册的批复》（证监许可〔2023〕1629 号）， 山东力诺医药包装股份有限公司（以下简称"公司"）于 2023 年 8 月 23 日向不 特定对象发行可转换公司债券 500.00 万张，每张面值为人民币 100 元，共计募 集资金 50,000.00 万元，债券简称"力诺转债"，债券代码"123221"。本次发 行的可转债转股期自可转债发行结束之日满六个月后的第一个交易日（20 ...

Core Viewpoint - The announcement from Lino Pharmaceutical indicates that investors can choose to sell their "Lino Convertible Bonds" at a price of 100.055 CNY per bond, including interest and tax, despite the market price being higher prior to the announcement [2] Summary by Category Company Announcement - Lino Pharmaceutical announced that investors have the option to redeem their "Lino Convertible Bonds" at a price of 100.055 CNY per bond [2] - The closing price of "Lino Convertible Bonds" was higher than the redemption price before the announcement [2] Investor Considerations - Investors opting for the redemption may incur losses due to the higher market price of the bonds [2]

Market Overview - The A-share market collectively rose on October 10, with the Shanghai Composite Index up 0.13%, the Shenzhen Component Index up 0.38%, and the ChiNext Index up 1.27%, while the North Stock 50 declined [2] - The total trading volume across the Shanghai, Shenzhen, and Beijing markets was 20,040 billion yuan, a decrease of 1,481 billion yuan compared to the previous day [2] - Over 2,400 stocks in the market experienced gains [2] Sector Performance - The leading sectors in terms of gains included oil and gas, film and television, satellite communication, tourism, gaming, and AI computing hardware [2] - Conversely, sectors that saw declines included energy metals, photovoltaic and wind power, PEEK materials, and solid-state battery concepts [2] Notable Stocks - AI computing hardware stocks rebounded collectively, with Industrial Fulian hitting the daily limit, and Shenghong Technology reaching a new high during the session [2] - Oil and gas stocks surged, with Zhun Oil shares hitting the daily limit [2] - The satellite communication sector maintained high volatility, with stocks like Yuandao Communication, 263, and Sanwei Communication reaching their daily limits [2] Active Sectors - The sports, gaming, and film and television sectors showed active performance during the session [2] Declining Stocks - Many stocks in the new energy sector, including photovoltaic and lithium battery stocks, adjusted downwards, with Shangneng Electric and Tianhong Lithium Battery dropping over 10% [2] - Other notable declines included Tianqi Lithium, Ganfeng Lithium, and JinkoSolar, among others [2]

| 证券代码：301188 | 证券简称：力诺药包 | 公告编号：2025-087 | | --- | --- | --- | | 债券代码：123221 | 债券简称：力诺转债 | | 东力诺特种玻璃股份有限公司创业板向不特定对象发行可转换公司债券募集说明 书》（以下简称"《募集说明书》"）约定，"力诺转债"的附加回售条款生效。 现将"力诺转债"回售有关事项公告如下： 一、回售情况概述 9、本次回售不具有强制性，持有人有权选择是否进行回售 10、风险提示：投资者选择回售等同于以 100.055 元/张（含息、税）卖出持 有的"力诺转债"。截至本公告发出前的最后一个交易日，"力诺转债"的收盘 价格高于本次回售价格。投资者选择回售可能会带来损失，敬请投资者注意风险。 山东力诺医药包装股份有限公司（以下简称"公司"）于 2025 年 8 月 19 日 召开第四届董事会第十二次会议和第四届监事会第十一次会议，并于 2025 年 9 月 5 日召开了"力诺转债"2025 年第一次债券持有人会议和 2025 年第二次临时 股东会，上述会议审议通过了《关于变更部分募集资金用途的议案》。根据《山 1 1、债券简称：力诺转债 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [2] Core Viewpoints - The green transformation accelerates the upgrade of the supply structure in the building materials industry, with a focus on innovative measures to promote the industry's shift towards green and intelligent development [4] - The report highlights the positive impact of government policies, such as the "Three-Year Action Plan for the Promotion of Green Building Materials Industry" in Hubei Province, which aims to reshape the industrial structure [4] - Key recommended companies include: Sanke Tree (channel penetration, retail expansion), Dongfang Yuhong (waterproof leader, operational structure optimization), Weixing New Materials (high-quality operations, high retail business proportion), and Jianlang Hardware [4] - Beneficiary stocks in the cement sector include: Conch Cement, Huaxin Cement, and Shangfeng Cement, with a focus on energy-saving and carbon reduction initiatives [4] Market Performance - The building materials index rose by 2.45% in the week from September 8 to September 12, outperforming the CSI 300 index by 1.07 percentage points [5][14] - Over the past three months, the CSI 300 index increased by 15.83%, while the building materials index rose by 21.65%, indicating a 5.83 percentage point outperformance [5][14] - In the past year, the CSI 300 index increased by 43.14%, while the building materials index rose by 52.13%, showing a 9.00 percentage point outperformance [5][14] Cement Sector - As of September 12, the average price of P.O42.5 bulk cement nationwide was 275.03 yuan/ton, with a slight increase of 0.01% month-on-month [27] - The clinker inventory ratio nationwide was 62.59%, down by 0.79 percentage points [28] - Regional price variations were noted, with Northeast prices decreasing by 2.17% and North China prices increasing by 2.22% [27][31] Glass Sector - The average price of float glass as of September 12 was 1202.33 yuan/ton, reflecting a week-on-week increase of 1.01% [78] - The inventory of float glass decreased by 1.86%, with a total of 55 million weight boxes [80] - The price of photovoltaic glass remained stable at 125.00 yuan/weight box [84] Valuation Metrics - The average price-to-earnings (PE) ratio for the building materials sector is 29.36 times, ranking it 15th from the bottom among all A-share industries [23] - The price-to-book (PB) ratio is 1.34 times, ranking it 8th from the bottom among all A-share industries [32]

Group 1 - The company Lino Pharmaceutical announced that investors can choose to sell their "Lino Convertible Bonds" at a price of 100.055 yuan per bond (including interest and tax) [1] - As of the last trading day before the announcement, the closing price of "Lino Convertible Bonds" was higher than the repurchase price [1] - The decision to sell may result in losses for investors, highlighting the need for caution [1]

| 证券代码：301188 | 证券简称：力诺药包 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：123221 | 债券简称：力诺转债 | | 山东力诺医药包装股份有限公司（以下简称"公司"）于 2025 年 8 月 19 日 召开第四届董事会第十二次会议和第四届监事会第十一次会议，并于 2025 年 9 月 5 日召开了"力诺转债"2025 年第一次债券持有人会议和 2025 年第二次临时 股东会，上述会议审议通过了《关于变更部分募集资金用途的议案》。根据《山 1 1、债券简称：力诺转债 2、债券代码：123221 3、回售价格：100.055 元/张（含息、税） 4、回售申报期：2025 年 9 月 12 日至 2025 年 9 月 18 日 5、发行人资金到账日：2025 年 9 月 23 日 6、回售款划拨日：2025 年 9 月 24 日 7、投资者回售款到账日：2025 年 9 月 25 日 8、回售申报期内"力诺转债"暂停转股 东力诺特种玻璃股份有限公司创业板向不特定对象发行可转换公司债券募集说明 书》（以下简称"《募集说明书》"）约定，"力诺转债"的 ...

Core Viewpoint - The company, Shandong Linuo Special Glass Co., Ltd., has signed a tripartite supervision agreement for fundraising with Minsheng Securities Co., Ltd. and CITIC Bank Jinan Branch, indicating a strategic move to secure funding through convertible bonds [1] Fundraising Details - The company plans to issue 5 million convertible bonds with a face value of 100 RMB each, totaling 500 million RMB in fundraising [1] - After deducting issuance costs, the net amount raised will be 491 million RMB [1] - A new fundraising special account has been opened at CITIC Bank Jinan Branch, and a new tripartite supervision agreement has been signed with the bank and the sponsor [1]